Engineers Gate Manager LP Avadel Pharmaceuticals PLC Transaction History

Engineers Gate Manager LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.07 - $6.95 $12,305 - $79,925	-11,500 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$5.46 - $8.29 $62,790 - $95,334	11,500 New	11,500 $79,000
Q3 2021 Nov 15, 2021	SELL	$6.49 - $9.91 $89,562 - $136,758	-13,800 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$6.73 - $9.05 $92,874 - $124,890	13,800 New	13,800 $93,000
Q4 2020 Feb 16, 2021	SELL	$5.03 - $7.95 $131,283 - $207,495	-26,100 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$5.02 - $8.98 $24,597 - $44,002	4,900 Added 23.11%	26,100 $132,000
Q2 2020 Aug 17, 2020	BUY	$7.25 - $11.75 $153,700 - $249,100	21,200 New	21,200 $171,000
Q1 2020 May 15, 2020	SELL	$4.06 - $10.64 $87,695 - $229,824	-21,600 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$3.34 - $7.7 $72,144 - $166,320	21,600 New	21,600 $163,000

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $650M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

Stay updated on Engineers Gate Manager LP with notifications on news.